Morphological and molecular comparison of HIV-associated and sporadic inclusion body myositis.
HIV-IBM
IBM-SD
Inclusion Body Myositis
KLRG1
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
20
03
2023
accepted:
11
05
2023
revised:
10
05
2023
medline:
14
8
2023
pubmed:
7
6
2023
entrez:
6
6
2023
Statut:
ppublish
Résumé
The molecular characteristics of sporadic inclusion body myositis (sIBM) have been intensively studied, and specific patterns on the cellular, protein and RNA level have emerged. However, these characteristics have not been studied in the context of HIV-associated IBM (HIV-IBM). In this study, we compared clinical, histopathological, and transcriptomic patterns of sIBM and HIV-IBM. In this cross-sectional study, we compared patients with HIV-IBM and sIBM based on clinical and morphological features as well as gene expression levels of specific T-cell markers in skeletal muscle biopsy samples. Non-disease individuals served as controls (NDC). Cell counts for immunohistochemistry and gene expression profiles for quantitative PCR were used as primary outcomes. 14 muscle biopsy samples (7 HIV-IBM, 7 sIBM) of patients and 6 biopsy samples from NDC were included. Clinically, HIV-IBM patients showed a significantly lower age of onset and a shorter period between symptom onset and muscle biopsy. Histomorphologically, HIV-IBM patients showed no KLRG1 Despite HIV-IBM and sIBM sharing important clinical, histopathological, and transcriptomic signatures, the presence of KLRG1
Identifiants
pubmed: 37280376
doi: 10.1007/s00415-023-11779-y
pii: 10.1007/s00415-023-11779-y
pmc: PMC10243696
doi:
Substances chimiques
Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4434-4443Informations de copyright
© 2023. The Author(s).
Références
Robinson-Papp J, Simpson DM (2009) Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 40(6):1043–1053
doi: 10.1002/mus.21465
pubmed: 19771594
pmcid: 2916755
Landon-Cardinal O, Gallay L, Dubourg O, Maisonobe T, Léonard-Louis S, Beniken D, Simon A, Behin A, Stojkovic T, Duyckaerts C, Breton G, Rigolet A, Fain O, Meyohas MC, Leport C, Valantin MA, Vittecoq D, Bergmann JF, Hanslik T, Chauveheid MP, Amoura Z, de Broucker T, Eymard B, Beaudequin N, Benveniste O, Allenbach Y (2019) Expanding the spectrum of HIV-associated myopathy. J Neurol Neurosurg Psychiatry 90(11):1296–1298. https://doi.org/10.1136/jnnp-2018-319419
doi: 10.1136/jnnp-2018-319419
pubmed: 30975823
Hiniker A, Daniels BH, Margeta M (2016) T-cell-mediated inflammatory myopathies in HIV-positive individuals: a histologic study of 19 cases. J Neuropathol Exp Neurol 75(3):239–245
doi: 10.1093/jnen/nlv023
pubmed: 26843609
pmcid: 5009472
Lloyd TE, Pinal-Fernandez I, Michelle EH, Christopher-Stine L, Pak K, Sacktor N et al (2017) Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology 88(15):1454–1460
doi: 10.1212/WNL.0000000000003821
pubmed: 28283597
pmcid: 5386438
Catalán M, Selva-O’Callaghan A, Grau JM (2014) Diagnosis and classification of sporadic inclusion body myositis (sIBM). Autoimmun Rev 13(4–5):363–366
doi: 10.1016/j.autrev.2014.01.016
pubmed: 24424185
Kleefeld F, Uruha A, Schänzer A, Nishimura A, Roos A, Schneider U et al (2022) Morphologic and molecular patterns of polymyositis with mitochondrial pathology and inclusion body myositis. Neurology 99(20):e2212–e2222
pubmed: 36195449
Lopez Angel CJ, Pham EA, Du H, Vallania F, Fram BJ, Perez K, Nguyen T, Rosenberg-Hasson Y, Ahmed A, Dekker CL, Grant PM, Khatri P, Maecker HT, Glenn JS, Davis MM, Furman D (2021) Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. Proc Natl Acad Sci USA 118(14):e2022928118. https://doi.org/10.1073/pnas.2022928118
doi: 10.1073/pnas.2022928118
pubmed: 33811141
pmcid: 8040665
Deeks SG, Verdin E, McCune JM (2012) Immunosenescence and HIV. Curr Opin Immunol 24(4):501–506
doi: 10.1016/j.coi.2012.05.004
pubmed: 22658763
Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G (2008) Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing 5:6
doi: 10.1186/1742-4933-5-6
pubmed: 18657274
pmcid: 2515281
Wertheimer AM, Bennett MS, Park B, Uhrlaub JL, Martinez C, Pulko V et al (2014) Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J Immunol 192(5):2143–2155
doi: 10.4049/jimmunol.1301721
pubmed: 24501199
Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M et al (2019) T-cell exhaustion in HIV infection. Immunol Rev 292(1):149–163
doi: 10.1111/imr.12823
pubmed: 31883174
pmcid: 7003858
Strioga M, Pasukoniene V, Characiejus D (2011) CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 134(1):17–32
doi: 10.1111/j.1365-2567.2011.03470.x
pubmed: 21711350
pmcid: 3173691
Knauss S, Preusse C, Allenbach Y, Leonard-Louis S, Touat M, Fischer N et al (2019) PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited. Neurol Neuroimmunol Neuroinflamm 6(3):e558
doi: 10.1212/NXI.0000000000000558
pubmed: 31044146
pmcid: 6467687
Greenberg SA (2019) Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 15(5):257–272
doi: 10.1038/s41584-019-0186-x
pubmed: 30837708
Greenberg SA, Pinkus JL, Kong SW, Baecher-Allan C, Amato AA, Dorfman DM (2019) Highly differentiated cytotoxic T cells in inclusion body myositis. Brain 142(9):2590–2604
doi: 10.1093/brain/awz207
pubmed: 31326977
Henson SM, Akbar AN (2009) KLRG1–more than a marker for T cell senescence. Age (Dordr) 31(4):285–291
doi: 10.1007/s11357-009-9100-9
pubmed: 19479342
Benveniste O, Allenbach Y (2019) Inclusion body myositis: accumulation of evidence for its autoimmune origin. Brain 142(9):2549–2551
doi: 10.1093/brain/awz229
pubmed: 31497859
Matsubara S, Suzuki S, Komori T (2022) Immunohistochemical phenotype of T cells invading muscle in inclusion body myositis. J Neuropathol Exp Neurol 81(10):825–835
doi: 10.1093/jnen/nlac067
pubmed: 35920309
Goyal NA, Coulis G, Duarte J, Farahat PK, Mannaa AH, Cauchii J et al (2022) Immunophenotyping of inclusion body myositis blood T and NK cells. Neurology 98(13):e1374–e1383
doi: 10.1212/WNL.0000000000200013
pubmed: 35131904
pmcid: 8967422
Goel N, Needham M, Soler-Ferran D, Cotreau MM, Escobar J, Greenberg S (2022) POS1342 Depletion of KLRG1+ T cells in a first-in-human clinical trial of ABC008 in inclusion body myositis (IBM). Ann Rheum Dis 81(Suppl 1):1008
doi: 10.1136/annrheumdis-2022-eular.2141
Rose MR (2013) 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 23(12):1044–1055
doi: 10.1016/j.nmd.2013.08.007
pubmed: 24268584
Casademont J, Barrientos A, Grau JM, Pedrol E, Estivill X, Urbano-Márquez A et al (1996) The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain 119(Pt 4):1357–1364
doi: 10.1093/brain/119.4.1357
pubmed: 8813297
Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M et al (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247(1):22–28
doi: 10.1007/s004150050005
pubmed: 10701893
Dobloug C, Walle-Hansen R, Gran JT, Molberg Ø (2012) Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol 30(6):838–842
pubmed: 22935197
Greenberg SA (2022) Inclusion body myositis: boundaries that may define transition to treatment refractoriness. Neurology 99(20):873–874
pubmed: 36195454